Polynesia: CESEC rejects experimentation with medical cannabis
Back in February 2020, Olivier Véran had expressed support for the expansion Regarding the French pilot program for medical cannabis in French Polynesia, the Economic, Social, and Cultural Council of French Polynesia has just issued a negative advisory opinion on this very extension.
In a statement, the Council cites several reasons:
«The CESEC reviewed a draft opinion on a proposed regional law authorizing a pilot program for the medical use of cannabis in French Polynesia.".
Given the significant progress made in several countries in Europe and the Americas—both in terms of scientific research and legal developments, as well as the risks currently faced by our patients suffering from serious illnesses— it is essential that the country’s authorities take all necessary steps to rapidly update health regulations in order to establish a framework for the medical use of cannabis.
The CESEC believes it is indeed urgent to meet the expectations of our patients and certain healthcare professionals by ensuring the safest possible use of medical cannabis.
»However, the institution is not convinced that such a pilot program would allow for a swift response to patients' high expectations."
The French trial is indeed struggling to exceed 600 patients, suffers from a lack of training and interest among healthcare professionals, and is prescribing the flowers only sparingly.
The CESEC believes, however, that such a pilot program would run up against several regulations:
- French Polynesia has no jurisdiction over biomedical research [Editor's note: that the experiment is not supposed to be]
- Resolution No. 78-137 of August 18, 1978, regulating toxic substances in French Polynesia, prohibits any use of cannabis
Since the CESEC’s opinion is merely advisory, we will now have to wait for the Polynesian Assembly to deliberate on the matter.
Following the introduction of a bill last September, the proposal was to be submitted «to the Council of Ministers for the regulatory portion, including, in particular, an amendment to the resolution on toxic substances, an agreement with the National Agency for Medicines Safety, and the accreditation of a «reference medical center,» in order to subsequently determine the number of Polynesian patients who could be included in the study.
CBD is said to promote athletic recovery, without improving performance
294 cannabis clubs in Chile: a booming movement with uneven distribution
Chronic Sciatica: New York Approves First Clinical Trial of a THC-Based Medication
United States: The DEA is accelerating the integration of medical cannabis at the federal level
Florida is nearing one million patients using medical cannabis
Uruguay Revives Its Plan to Allow Tourists to Legally Access Cannabis
In Brazil, researchers are developing an innovative CBD eye drop
Autism: Medical Cannabis Is Linked to Reduced Anxiety
The $28 billion U.S. hemp market remains under threat
Jamaica Eases Small Farmers' Access to the Cannabis Market
-
Business5 days agoThe legal cannabis market in New York exceeds 4 billion $ in revenue
-
Cannabis and driving4 weeks ago
Cannabis and CBD: French Drivers Can Now Lose Their License Even Without a Positive Test Result
-
Cannabis in France2 weeks agoWhich countries legalized medical cannabis before France?
-
Business2 weeks ago
South Korea is preparing to begin local production of medical cannabis to meet rising demand
-
Cannabis in the Netherlands4 weeks ago
One year after the launch of the Dutch cannabis experiment, the first trends are emerging
-
Cannabis in Thailand2 weeks ago
From the boom in dispensaries to a purely medical approach: Thailand is revising its cannabis policy
-
Cannabis in France4 weeks ago
French medical cannabis remains stalled at the Ministry of Health
-
Cannabis in Argentina3 weeks ago
Argentina Opens Its Market to Hemp Flowers Containing 1% of THC
adory
November 3, 2021 at 9:20 a.m.
The problem with this experiment is that it was set up to fail. Between the obstacles and roadblocks set up by the Ministry of the Interior—which refuses to even consider it—and the incredibly bureaucratic red tape imposed by the ANSM, which turns even the slightest effort to include a patient into an obstacle course, if we reach 1,000 patients by the end of the pilot program, it will be nothing short of a miracle.
Not to mention the absurd inclusion criteria required by the ANSM; for example, it’s impossible to include a patient undergoing chemotherapy, even though that was one of the first therapeutic uses of cannabis in the 1970s. Dr. Grinspoon must be turning in his grave.
This experiment shows—if any proof were needed—that when it comes to this issue, French politicians are not only completely closed-minded but also manage to combine bad faith with ill will.